Jiangsu NHWA Gets China Fast-Track Status For D-Pharm's Epilepsy Drug
This article was originally published in PharmAsia News
Executive Summary
China's Jiangsu NHWA Pharmaceutical has won fast-track status from the China FDA for its DP-VPA (valproic acid) drug developed with Israel's D-Pharm to treat epilepsy.